Clinical Edge Journal Scan

Cumulative airborne dioxin exposure increases CLL and SLL risk


 

Key clinical point: Cumulative airborne dioxin exposure is significantly associated with an increased risk for non-Hodgkin's lymphoma (NHL), particularly for combined chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Major finding: A significant association was observed between log-transformed cumulative dioxin exposure index scores and the risk for NHL (adjusted odds ratio [aOR] 1.2; 95% CI 1.0-1.4), especially in case of the CLL and SLL subtypes (aOR 1.6; 95% CI 1.1-2.3), for a 4.4 log µg-toxic equivalent quantity/m 2 increase corresponding to a standard deviation.

Study details: This case-control study was nested within the prospective French National Institute for Health and Medical Research E3N cohort and included 368 women with NHL and 368 matched control women without NHL.

Disclosures: The E3N cohort was established and maintained with the support of the Mutuelle Générale de l'Education Nationale, France, and other sources. The authors declared no conflicts of interest.

Source: Gaspard E et al. Association between cumulative airborne dioxin exposure and non-Hodgkin's lymphoma risk in a nested case-control study within the French E3N cohort. Sci Total Environ. 2023;906:167330 (Sep 29). doi: 10.1016/j.scitotenv.2023.167330

Recommended Reading

Bendamustine a safe alternative to fludarabine/cyclophosphamide lymphodepletion for axi-cel therapy in aggressive BCL
B-Cell Lymphoma ICYMI
Past or active HBV infection associated with an increased risk for DLBCL
B-Cell Lymphoma ICYMI
Radiation therapy achieves effective palliation in MCL patients undergoing CAR T‐cell therapy
B-Cell Lymphoma ICYMI
Chemosensitivity helps predict survival outcomes after CAR T-cell therapy for DLBCL
B-Cell Lymphoma ICYMI
Commentary: Genetics, prognosis score, and PI3K in MCL, October 2023
B-Cell Lymphoma ICYMI
Second-line axi-cel therapy yields high response rates in high-risk relapsed or refractory LBCL
B-Cell Lymphoma ICYMI
Second-line vs later-line zanubrutinib improves survival in relapsed or refractory MCL
B-Cell Lymphoma ICYMI
High-dose methotrexate does not reduce CNS progression risk in high-risk aggressive BCL
B-Cell Lymphoma ICYMI
Ibrutinib maintenance after frontline induction is effective in mantle cell lymphoma
B-Cell Lymphoma ICYMI
Ibrutinib and bortezomib combo durably effective in relapsed or refractory MCL with high-risk features
B-Cell Lymphoma ICYMI